New studies provide insights into cancer mechanisms and potential therapies. A large multi-center retrospective study found that ovarian function suppression improves outcomes in premenopausal HR+/HER2+ breast cancer. Another investigation revealed that c-Abl inhibition suppresses glioma cell proliferation and invasiveness, suggesting novel therapeutic targets. Additionally, research links treatment resistance in ER+ breast cancer to suppression of the JNK signaling pathway, informing precision oncology strategies.